CenterBook Partners LP bought a new stake in shares of Glaukos Corporation (NYSE:GKOS – Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 13,257 shares of the medical instruments supplier’s stock, valued at approximately $1,497,000.
Other institutional investors have also modified their holdings of the company. Wellington Management Group LLP boosted its holdings in shares of Glaukos by 10.4% in the 3rd quarter. Wellington Management Group LLP now owns 3,580,670 shares of the medical instruments supplier’s stock worth $292,004,000 after purchasing an additional 336,266 shares during the period. Primecap Management Co. CA lifted its stake in Glaukos by 23.3% in the third quarter. Primecap Management Co. CA now owns 2,253,788 shares of the medical instruments supplier’s stock worth $183,796,000 after purchasing an additional 425,790 shares during the last quarter. State Street Corp grew its stake in shares of Glaukos by 5.3% during the second quarter. State Street Corp now owns 2,090,365 shares of the medical instruments supplier’s stock valued at $215,914,000 after buying an additional 105,972 shares during the last quarter. Ameriprise Financial Inc. lifted its stake in shares of Glaukos by 3.5% during the 2nd quarter. Ameriprise Financial Inc. now owns 1,999,252 shares of the medical instruments supplier’s stock worth $206,503,000 after acquiring an additional 68,497 shares during the last quarter. Finally, Alliancebernstein L.P. grew its position in Glaukos by 38.5% in the 3rd quarter. Alliancebernstein L.P. now owns 1,733,474 shares of the medical instruments supplier’s stock valued at $141,365,000 after acquiring an additional 481,620 shares during the last quarter. 99.04% of the stock is owned by institutional investors.
Analyst Ratings Changes
GKOS has been the subject of a number of recent analyst reports. Wells Fargo & Company boosted their target price on shares of Glaukos from $135.00 to $138.00 and gave the company an “overweight” rating in a research note on Thursday, April 30th. Needham & Company LLC raised their price target on shares of Glaukos from $127.00 to $136.00 and gave the stock a “buy” rating in a research note on Thursday, April 30th. William Blair reiterated an “outperform” rating on shares of Glaukos in a report on Tuesday, May 26th. BTIG Research boosted their price objective on shares of Glaukos from $141.00 to $162.00 and gave the company a “buy” rating in a research report on Thursday, May 21st. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Glaukos in a research note on Tuesday, April 21st. Twelve investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $146.17.
Glaukos Price Performance
GKOS opened at $126.72 on Wednesday. The company has a market capitalization of $7.44 billion, a price-to-earnings ratio of -38.63 and a beta of 0.82. The company has a current ratio of 5.43, a quick ratio of 4.73 and a debt-to-equity ratio of 0.10. Glaukos Corporation has a 12-month low of $73.16 and a 12-month high of $148.11. The business’s fifty day simple moving average is $123.04 and its 200-day simple moving average is $115.74.
Glaukos (NYSE:GKOS – Get Free Report) last released its quarterly earnings data on Wednesday, April 29th. The medical instruments supplier reported ($0.18) earnings per share for the quarter, beating the consensus estimate of ($0.30) by $0.12. The firm had revenue of $150.57 million during the quarter, compared to the consensus estimate of $137.00 million. Glaukos had a negative return on equity of 6.92% and a negative net margin of 34.34%.The firm’s quarterly revenue was up 41.2% on a year-over-year basis. During the same period in the previous year, the company posted ($0.22) earnings per share. On average, equities research analysts anticipate that Glaukos Corporation will post -0.57 earnings per share for the current fiscal year.
Insider Buying and Selling at Glaukos
In other Glaukos news, Director Gilbert H. Kliman sold 5,000 shares of the stock in a transaction on Thursday, May 14th. The stock was sold at an average price of $140.76, for a total transaction of $703,800.00. Following the sale, the director owned 35,528 shares of the company’s stock, valued at approximately $5,000,921.28. This trade represents a 12.34% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Leana Wen sold 1,700 shares of Glaukos stock in a transaction on Friday, May 1st. The shares were sold at an average price of $143.35, for a total value of $243,695.00. Following the completion of the transaction, the director owned 19,739 shares in the company, valued at $2,829,585.65. This represents a 7.93% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 45,930 shares of company stock valued at $6,321,363. 5.90% of the stock is owned by corporate insiders.
About Glaukos
Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.
Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.
Featured Stories
- Five stocks we like better than Glaukos
- The Bank of Mom and Dad Is Booming—3 Stocks to Watch
- Corning Is Paving AI’s Future With Glass
- Why’s Amazon Suddenly Lagging the S&P 500, and Is It a Warning?
- Crypto Winter Is Here: 3 Stocks To Put On Ice This Summer
Want to see what other hedge funds are holding GKOS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Glaukos Corporation (NYSE:GKOS – Free Report).
Receive News & Ratings for Glaukos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos and related companies with MarketBeat.com's FREE daily email newsletter.
